Your browser doesn't support javascript.
loading
Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic.
Souza, José Diogo S; Zuardi, Antonio W; Guimarães, Francisco S; Osório, Flávia de Lima; Loureiro, Sonia Regina; Campos, Alline Cristina; Hallak, Jaime E C; Dos Santos, Rafael G; Machado Silveira, Isabella Lara; Pereira-Lima, Karina; Pacheco, Julia Cozar; Ushirohira, Juliana Mayumi; Ferreira, Rafael Rinaldi; Costa, Karla Cristinne Mancini; Scomparin, Davi Silveira; Scarante, Franciele Franco; Pires-Dos-Santos, Isabela; Mechoulam, Raphael; Kapczinski, Flávio; Fonseca, Benedito A L; Esposito, Danillo L A; Andraus, Maristela Haddad; Crippa, José Alexandre S.
Afiliación
  • Souza JDS; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Zuardi AW; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Guimarães FS; National Institute for Science and Technology-Translational Medicine, Ribeirão Preto, Brazil.
  • Osório FL; National Institute for Science and Technology-Translational Medicine, Ribeirão Preto, Brazil.
  • Loureiro SR; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Campos AC; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Hallak JEC; National Institute for Science and Technology-Translational Medicine, Ribeirão Preto, Brazil.
  • Dos Santos RG; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Machado Silveira IL; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Pereira-Lima K; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Pacheco JC; National Institute for Science and Technology-Translational Medicine, Ribeirão Preto, Brazil.
  • Ushirohira JM; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Ferreira RR; National Institute for Science and Technology-Translational Medicine, Ribeirão Preto, Brazil.
  • Costa KCM; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Scomparin DS; University of Michigan Medical School, Ann Arbor, IN, United States.
  • Scarante FF; Department of Psychiatry, Federal University of São Paulo, São Paulo, São Paulo, Brazil.
  • Pires-Dos-Santos I; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Mechoulam R; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Kapczinski F; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Fonseca BAL; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Esposito DLA; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Andraus MH; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Crippa JAS; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Front Pharmacol ; 13: 856846, 2022.
Article en En | MEDLINE | ID: mdl-36263136
Objective: To assess whether the effects of oral administration of 300 mg of Cannabidiol (CBD) for 28 days on mental health are maintained for a period after the medication discontinuation. Methods: This is a 3-month follow-up observational and clinical trial study. The data were obtained from two studies performed simultaneously by the same team in the same period and region with Brazilian frontline healthcare workers during the COVID-19 pandemic. Scales to assess emotional symptoms were applied weekly, in the first month, and at weeks eight and 12. Results: The primary outcome was that, compared to the control group, a significant reduction in General Anxiety Disorder-7 Questionnaire (GAD-7) from baseline values was observed in the CBD group on weeks two, four, and eight (Within-Subjects Contrasts, time-group interactions: F1-125 = 7.67; p = 0.006; ηp 2 = 0.06; F1-125 = 6.58; p = 0.01; ηp 2 = 0.05; F1-125 = 4.28; p = 0.04; ηp 2 = 0.03, respectively) after the end of the treatment. Conclusions: The anxiolytic effects of CBD in frontline health care professionals during the COVID-19 pandemic were maintained up to 1 month after the treatment discontinuation, suggesting a persistent decrease in anxiety in this group in the real world. Future double-blind placebo-controlled clinical trials are needed to confirm the present findings and weigh the benefits of CBD therapy against potential undesired or adverse effects.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Suiza